Ipsen

IPN

FR0010259150

Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (75.2%); - neuroscience (21.1%); - rare diseases (3.7%). At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide. Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).

Sector

Pharmaceuticals

Calendar

2024-04-24 - Q1 2024 Sales and Revenue Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

IPSEN : Ipsen’s underlying fundamentals remain promising

March 13, 2024 at 11:50 am EDT

More Strategies

Ratings for Ipsen

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

108.4 EUR

Average target price

124.6 EUR

Spread / Average Target

+14.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
IPSEN	-0.28%	9.52B
ELI LILLY AND COMPANY	+28.45%	676B
NOVO NORDISK A/S	+24.27%	559B
JOHNSON & JOHNSON	-7.76%	356B
MERCK & CO., INC.	+15.13%	320B
ABBVIE INC.	+5.07%	286B
ASTRAZENECA PLC	+2.62%	213B
NOVARTIS AG	+0.15%	207B
ROCHE HOLDING AG	-9.41%	199B
AMGEN INC.	-7.80%	142B

Other Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:35:18 2024-04-16 am EDT			After market 03:50:00 pm
107.6 ^EUR	-0.74%		107.5	-0.09%

Apr. 15	Ipsen: Parvus AM Europe Ltd exceeds 5% of voting rights	CF
Apr. 02	Ipsen: worldwide licensing agreement with Sutro Biopharma	CF

Ipsen: Parvus AM Europe Ltd exceeds 5% of voting rights	Apr. 15	CF
Ipsen: worldwide licensing agreement with Sutro Biopharma	Apr. 02	CF
Ipsen Signs Licensing Deal for Cancer-targeting Antibody Conjugate with Sutro Biopharma	Apr. 02	MT
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	Mar. 27	MT
IPSEN : Ipsen’s underlying fundamentals remain promising	Mar. 13
Deutsche Bank Reduces Ipsen PT, Keeps Hold Rating	Feb. 16	MT
IPSEN : Deutsche Bank cuts its target	Feb. 16	CF
IPSEN : UBS reiterates its buy recommendation	Feb. 14	CF
Merrimack Pharmaceuticals to Receive $225 Million Milestone Payment From Ipsen	Feb. 14	MT
Ipsen: new indication approved in pancreatic cancer	Feb. 14	CF
US FDA OKs Ipsen's Metastatic Pancreatic Adenocarcinoma Treatment Regimen in Adults	Feb. 13	MT
Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval	Feb. 13	DJ
Ipsen?s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA	Feb. 13	CI
Ipsen S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
IPSEN : In line Q4 sales; lower-than-expected 2024 guidance	Feb. 08
Transcript : Ipsen S.A., 2023 Earnings Call, Feb 08, 2024	Feb. 08
Ipsen: 13% drop in annual EPS	Feb. 08	CF
Transcript : Ipsen S.A., 2023 Pre Recorded Earnings Call, Feb 08, 2024	Feb. 07
Ipsen presents positive data for Cabometyx	Jan. 23	CF
Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024	Jan. 22	CI
IPSEN : Deutsche Bank lowers its target price	Dec. 15	CF
IPSEN : Ipsen outlined some promising mid-term takeaways at the CMD	Dec. 08
IPSEN : UBS remains Buy after CMD	Dec. 08	CF
Genfit: upbeat after updated outlook	Dec. 08	CF
Transcript : Ipsen S.A. - Analyst/Investor Day	Dec. 07